Navigation Links
Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
Date:10/25/2007

in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients for a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed an oral formulation of the active ingredient in Ganite that is currently undergoing initial clinical trials as a potential treatment for diseases associated with accelerated bone loss. Genta is partnered with IDIS (http://www.idispharma.com) on a program whereby both Ganite(R) and Genasense(R) are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:


'/>"/>
SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Sonic Foundry completes $11.25M stock offer
2. Orion Energy completes $5M capital round
3. RedPrairie completes MARC acquisition
4. Metavante completes purchase of check processing firm
5. GE completes $1.2 billion acquisition
6. M & Is Metavante completes Brasfield Corp. acquisition
7. Metavante completes GHR Systems acquisition
8. Metavante completes TREEV acquisition
9. Johnson Controls completes sale of French unit
10. OpGen completes $5 million investment round
11. UW Hospital completes deployment of error-reducing technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... October 01, 2014 TeselaGen Biotechnology ... Science Foundation to expand their bioCAD/CAM software suite, which ... modify DNA. The Small Business Innovation Research Phase II ... technology under exclusive license from the Lawrence Berkeley National ... Institute , an LBNL laboratory that develops alternative fuel ...
(Date:10/1/2014)... 1, 2014 Industry leaders ... to engage around the theme, ,Commercial Opportunities in the ...   Elsevier , a world-leading provider ... will host a gathering of some of the industry,s ... impacting healthcare today and in the future. The ...
(Date:9/30/2014)... news release is available in German . ... the Technische Universitt Mnchen (TUM) have demonstrated a new ... experiments show that future computer chips could be based ... As the main enabling technology of the semiconductor industry ... limits, the TUM researchers and collaborators at the University ...
(Date:9/30/2014)... 2014 Report Details Biosimilar drugs ... revenues Do you want to find sales potentials ... predictions for those biological drugs from 2014, helping ... financial data, R&D trends, opportunities and selling prospects. ... to 2024 at overall world market, therapeutic class, ...
Breaking Biology Technology:TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5
... ATLANTA, Georgia , March 14, 2010 ... type 2 diabetes patients with,atherogenic dyslipidemia, the common combination of ... low levels of high-density,lipoprotein cholesterol (HDL-C, 34 mg/dL or 0.88 ... Only 20 of these patients need,to be treated for 5 ...
... ... is taking strides to expand their Product and Material Testing Division by promoting Mark Francis ... Minneapolis, ... and material testing, is taking strides to expand their Product and Material Testing Division by ...
... FRANCISCO , March 12 Medivation, Inc. (Nasdaq: MDVN ) today announced that it will ... a general business update on March 15, 2010 , at 4:30 p.m. Eastern Time . A ... after markets close on March 15, 2010 . , ... ...
Cached Biology Technology:ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 2ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 3ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 4ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 5ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 6ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 7ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 8ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 9DDL Expands the Product & Material Testing Division 2DDL Expands the Product & Material Testing Division 3Medivation Announces Fourth Quarter and Year-End 2009 Financial Results Teleconference and Webcast On March 15, 2010 2Medivation Announces Fourth Quarter and Year-End 2009 Financial Results Teleconference and Webcast On March 15, 2010 3
(Date:10/2/2014)... The global genomics market was valued at $11.11 billion ... CAGR of over 12.0% from 2013 to 2018. The ... applications, and advancements in existing technologies plays an important ... this market. Next Generation Sequencing (NGS) in personalized medicine ... area for the global genomics market. This new technology ...
(Date:10/1/2014)... Reserve University researchers hope to take a healthy salad ... aggressive form of breast cancer in leafy greens. , ... the vaccine either by eating the salad or making ... assistant professor of biomedical engineering at Case Western Reserve ... The Susan G. Komen breast cancer organization is funding ...
(Date:10/1/2014)... Novel detection technology is ... The life science field has seen ... years. Some are shooting stars and others become ... detection technology that has raised much enthusiasm among ... is becoming commercially available. With their unique advantages, ...
Breaking Biology News(10 mins):Genomics Market by Products - [Instruments (NGS platform, Microarray, RT-PCR), Consumables (Genechips, Reagents for DNA Extraction & Purification, Sequencing)], Services (Sequencing & Microarray Services, and Software) - Global Forecast to 2018 2Scientists wield plant viruses against deadly human disease 2Scientists wield plant viruses against deadly human disease 3First-of-a-kind Solution for Utilizing Photon Upconversion 2
... The International Council for Science (ICSU), within ... major 10-year initiative which aims to effectively deliver ... This new international collaboration effort, the Earth System ... to respond to the most pressing societal and ...
... key regulator that controls the speed of development in the ... regulator, animals sped up their rate of development and reached ... A research team, led by molecular geneticist Kirst King-Jones, noticed ... The protein acted as a sentinel to either allow or ...
... inequality around the world, the Journal of Visualized ... through the HINARI initiative to developing countries in South ... in biological research, JoVE is the first and only ... publishes video articles demonstrating advanced experiments performed in laboratories ...
Cached Biology News:Research solutions for sustainability in a rapidly changing world 2JoVE grants developing countries access to experimental videos 2
... Rabbit polyclonal to Taura ... Abpromise for all tested ... Synthetic peptide: VTNSEGSTIL MNDIPITNQN ... ATEFNQ, corresponding to N terminal ...
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
... Anti-acetyl-Histone H3 (Lys 4) ... the sequence ...RT[ Ac K]Q... in which ... 4 of human histone H3 ... Molecular Weight: Mr ~17kDa ...
Blank Calibration Particles, 3.0-3.4 mu m 5 ml...
Biology Products: